Asset Details
Do you wish to reserve the book?
How to develop viruses into anticancer weapons
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
How to develop viruses into anticancer weapons
Do you wish to request the book?
How to develop viruses into anticancer weapons
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
/ Mail
How to develop viruses into anticancer weapons
2017
Overview
About the Authors: Roberto Cattaneo * E-mail: Cattaneo.Roberto@mayo.edu Affiliation: Department of Molecular Medicine and Virology and Gene Therapy Graduate School track, Mayo Clinic, Rochester, Minnesota, United States of America Stephen J. Russell Affiliation: Department of Molecular Medicine and Virology and Gene Therapy Graduate School track, Mayo Clinic, Rochester, Minnesota, United States of AmericaCitation: Cattaneo R, Russell SJ (2017) How to develop viruses into anticancer weapons. Competing interests: SJR is a scientific cofounder, equity stakeholder, board member and serves as CEO at Vyriad, a company that is developing oncolytic measles viruses for cancer therapy. In the mid-20th century, the principle of virus attenuation through adaptation to unnatural hosts was extended to cultured cells: cells from different species were used to select viruses with multiple mutations, reducing replication speed and allowing the immune system to control viral infection. [...]subunit vaccines are proving to be effective against virus-induced cancers, preventing hepatitis B virus-induced hepatocellular carcinoma and human papilloma virus-induced cervical cancer [2, 4]. Intentional transmission of virus infections was then pursued in a range of cancer types using several different virus isolates (most notably West Nile, mumps, and adenovirus) and led to definite tumor regressions but sometimes also to fatal encephalitis, as with West Nile virus in immunosuppressed lymphoma patients [8]. [...]the vaccine lineage-based measles virus (MeV) platform we have developed can enter many cell types through the ubiquitously expressed protein CD46, while future clinical trials may be based on viruses with targeted tropism. [...]targeted cell entry and cell-cell fusion: the two-protein MeV...
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antineoplastic Agents - immunology
/ Antineoplastic Agents - pharmacology
/ Cancer
/ Cervix
/ Humans
/ Lymphoma
/ Measles
/ Medicine
/ Medicine and Health Sciences
/ Mumps
/ Mutation
/ Oncolytic Virotherapy - methods
/ Oncolytic Virotherapy - trends
/ Oncolytic Viruses - immunology
/ Pearls
/ Proteins
/ Smallpox
/ Tropism
/ Vaccines
/ Virology
/ Viruses
/ Weapons
